Compugen

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Retrieved on: 
Monday, March 11, 2024
Compugen, Therapy, Research, Immunotherapy

HOLON, Israel, March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada.

Key Points: 
  • HOLON, Israel, March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada.
  • "We are delighted to be selected to give two oral presentations at the upcoming Keystone Symposium on Cancer Immunotherapy this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
  • "We believe our selection to present at a Keystone Symposium reflects the significant discovery, research and development taking place at Compugen as we are working to advance our vision to transform patient lives by developing first-in class therapeutics based on our computational target discovery platform."

AdhereTech Announces Appointment of Paul Sekhri to Board of Directors

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Senior, TPG Inc., Aidia, Teva, Integrated care, Business development, Sanofi, Chairperson, Therapy, Evaluation, Patient, Teva Pharmaceuticals, Compugen, Pharmaceutical industry

SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.

Key Points: 
  • SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.
  • “We are excited to have Paul join the AdhereTech Board of Directors,” commented Neale Trangucci, Chair of the Board.
  • Paul Sekhri added: “I welcomed the opportunity to join the Board of AdhereTech as I see that the company’s Aidia real-time adherence technology can effectively address a major issue - non-adherence to medication.
  • I look forward to working with my fellow Board members and the management team to help ensure AdhereTech’s solutions get to those who need them.”

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Immunotherapy, AACR, Cytokine, Tumor microenvironment, Abstract, TIGIT, PVRIG, Biology, Compugen, Pharmaceutical industry

HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.

Key Points: 
  • HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.
  • "It is exciting that the progress we have made to potentially address immunotherapy resistance from diverse angles will be reflected at AACR this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
  • Eran Ophir, Ph.D., Chief Scientific Officer at Compugen, added, "At ACCR we will present data supporting the unique biology of PVRIG suggesting its role in sensitizing tumors to other immune checkpoints TIGIT and PD-(L)1.
  • The data will be published in the online Proceedings supplement to the AACR journal Cancer Research prior to the meeting on Friday, March 22, 2024.

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
Monday, February 26, 2024
Immunotherapy, Compugen, Conference

HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, on Monday, March 11, 2024 at 11:20 AM ET.

Key Points: 
  • HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, on Monday, March 11, 2024 at 11:20 AM ET.
  • A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at www.cgen.com .
  • A replay will be available following the live event.

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

Retrieved on: 
Tuesday, February 20, 2024
Telephone, Immunotherapy, Compugen, Broadcasting

2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, before the U.S. financial markets open.

Key Points: 
  • 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, before the U.S. financial markets open.
  • Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
  • To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally.
  • The call will be available via live webcast through Compugen's website, located at the following link.

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Retrieved on: 
Thursday, February 15, 2024
Therapy, Acquisition, Gilead Sciences, Immunotherapy, University of the Witwatersrand, Johnson & Johnson, Pleasure, NewYork-Presbyterian Hospital, Lead, University, Patient, Anat, Mount Sinai Medical Center, Drug, Compugen, Pharmaceutical industry

HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.

Key Points: 
  • HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.
  • Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.
  • "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.
  • Michelle obtained her medical degree from University of the Witwatersrand, South Africa and is a board-certified pediatric hematologist and oncologist.

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024
Oncology, Health, Infectious Diseases, Hospitals, COVID-19, Pharmaceutical, Biotechnology, EPS, IPR, Compugen, Immunotherapy, Food and Drug Administration, ETR, Dow Jones Sustainability Indices, Progression-free survival, Obeldesivir, FDA, Virology, FTC, Hematology, ALL, HDV, Society, Neurotoxicity, Acquisition, HCV, Cell therapy, Acute lymphoblastic leukemia, MYR, Research, HIV, Patient, Tenofovir alafenamide, Food, Infection, Multiple myeloma, Standard of care, OS, Lymphoma, B-cell lymphoma, Table, GAAP, Docetaxel, Lung cancer, Science, Earnings per share, Investment, Liver disease, Risk, ASH, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
  • During the fourth quarter 2023, Gilead paid cash dividends of $943 million and utilized $150 million to repurchase common stock.
  • The Liver Disease portfolio sales were $691 million in the fourth quarter 2023 and remained flat compared to the same period in 2022.
  • Cell Therapy product sales increased 11% to $466 million in the fourth quarter 2023 compared to the same period in 2022.

Compugen Welcomes Kara Rudy as Vice President, Marketing

Retrieved on: 
Monday, January 22, 2024
Research, Worldview, Software as a service, Consultant, Cancer, Data, Acquisition, CMO, Marketing, Compugen, Growth

RICHMOND HILL, ON, Jan. 22, 2024 /PRNewswire/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is pleased to announce MarketDesign Consulting Founder + CMO Kara Rudy has officially joined Compugen Inc. as its new Vice President, Marketing, effective January 1.

Key Points: 
  • RICHMOND HILL, ON, Jan. 22, 2024 /PRNewswire/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is pleased to announce MarketDesign Consulting Founder + CMO Kara Rudy has officially joined Compugen Inc. as its new Vice President, Marketing, effective January 1.
  • Instrumental in the new brand, website, and World View portfolio refresh for Compugen Inc. that launched in late 2023, Kara and her team at MarketDesign have been consultants working closely with Compugen Inc. for two years.
  • I'm excited to continue to support Compugen Inc., and join the Compugen Group of Companies in an official capacity.
  • Reporting to Terry, Kara will foster connections across teams, departments, partners, and stakeholders with a focus on modern marketing and building data-driven go-to-market strategies.

Compugen Welcomes Kara Rudy as Vice President, Marketing

Retrieved on: 
Monday, January 22, 2024
Research, Worldview, Software as a service, Consultant, Cancer, Data, Acquisition, CMO, Marketing, Compugen, Growth

RICHMOND HILL, ON, Jan. 22, 2024 /PRNewswire/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is pleased to announce MarketDesign Consulting Founder + CMO Kara Rudy has officially joined Compugen Inc. as its new Vice President, Marketing, effective January 1.

Key Points: 
  • RICHMOND HILL, ON, Jan. 22, 2024 /PRNewswire/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is pleased to announce MarketDesign Consulting Founder + CMO Kara Rudy has officially joined Compugen Inc. as its new Vice President, Marketing, effective January 1.
  • Instrumental in the new brand, website, and World View portfolio refresh for Compugen Inc. that launched in late 2023, Kara and her team at MarketDesign have been consultants working closely with Compugen Inc. for two years.
  • I'm excited to continue to support Compugen Inc., and join the Compugen Group of Companies in an official capacity.
  • Reporting to Terry, Kara will foster connections across teams, departments, partners, and stakeholders with a focus on modern marketing and building data-driven go-to-market strategies.

Adimab Provides 2023 Update on Clinical Pipeline

Retrieved on: 
Tuesday, January 9, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Engineering, Antibody, CD3, G protein-coupled receptor, Cytokine, Immunoglobulin G, Partner, Sintilimab, HC, Spacecraft, CD28, Complex, Protein, BLA, Compugen, Eurosport 1, FC, Vaccine

This brings the total number of Adimab partner programs that have entered the clinic to 74.

Key Points: 
  • This brings the total number of Adimab partner programs that have entered the clinic to 74.
  • Two additional products were approved and another BLA was filed in 2023.
  • “We are thrilled to have 12 new clinical programs initiated in 2023, especially given the constrained financial market that has impacted so many biotech companies over the past few years,” said Philip T. Chase, Chief Executive Officer of Adimab.
  • For these targets, Adimab has developed proprietary in vitro and in vivo discovery workflows that allow for discovery against membrane-obligate proteins in their native state.